Find a Parkview Health Clinical Trial
6 results found
Current Studies
Primary The primary objective of this Phase 2 study is to evaluate the safety of Epcoritamab monotherapy without mandatory hospitalization for the first full dose of Epcoritamab in subjects with R/R DLBCL or R/R FL Grade 1-3a who have received at least 2 prior lines of systemic anti-lymphoma...
Primary Outcome Measures : Time from randomization until treatment failure [ Time Frame: Randomization to until end of study (up to 39 months after randomization of last participant) ] Time from randomization until treatment failure is defined as the time from randomization date until the first of...
The primary objective of this study is to evaluate whether the addition of epcoritamab to 6 cycles of standard R-CHOP followed by 2 cycles of epcoritamab (E + R-CHOP) can prolong PFS compared with 6 cycles of standard R-CHOP followed by 2 cycles of rituximab (R-CHOP) in subjects with newly...
Primary objective(s) To demonstrate that either dose of ianalumab induces durable hemoglobin (Hb) response compared to placebo, in patients with wAIHA who failed at least one previous line of treatment Secondary objective(s) Key secondary objective: to demonstrate that either dose of ianalumab...
Primary Outcome Measures : Time from randomization to treatment failure (TTF) [ Time Frame: Randomization to end of study (up to 39 months after randomization of last patient) ] Time from randomization until platelet count below 30 G/L, need for a rescue treatment or start of a second-line therapy...